Literature DB >> 22688930

Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.

Marit Mejhert1, Robert Hast, Benngt Sandstedt, Izabella Janczewska.   

Abstract

The prognosis in amyloid light chain (AL)-amyloidosis and multiorgan involvement is poor, with a high-treatment-related mortality after high-dose melphalan and autologous stem cell transplantation (HDM/SCT). Some patients, however, might benefit from the therapy. We report a case of cardiac AL-amyloidosis with multiorgan involvement where the progressive cardiomyopathy was halted after successful treatment with HDM/SCT in 2001. The patient is in an excellent cardiac condition with a good quality of life, receiving treatment with angiotensinogen receptor blockers and a flexible diuretics regimen at follow-up after 10 years.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22688930      PMCID： PMC3171029          DOI： 10.1136/bcr.03.2011.4007

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  31 in total

1.  Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; Terry M Therneau; Dirk R Larson; Matthew F Plevak; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; Morie A Gertz
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

2.  Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.

Authors:  Philippe Moreau; Arnaud Jaccard; Lotfi Benboubker; Bruno Royer; Xavier Leleu; Franck Bridoux; Gilles Salles; Veronique Leblond; Murielle Roussel; May Alakl; Olivier Hermine; Lucie Planche; Jean-Luc Harousseau; Jean-Paul Fermand
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

3.  High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement.

Authors:  P Moreau; N Milpied; P de Faucal; T Petit; P Herbouiller; R Bataille; J L Harousseau
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

4.  Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.

Authors:  P Moreau; V Leblond; P Bourquelot; T Facon; A Huynh; D Caillot; O Hermine; M Attal; M Hamidou; G Nedellec; A Ferrant; B Audhuy; R Bataille; N Milpied; J L Harousseau
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

5.  Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).

Authors:  M A Gertz; M Q Lacy; D A Gastineau; D J Inwards; M G Chen; A Tefferi; R A Kyle; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2000-11       Impact factor: 5.483

6.  Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Authors:  R L Comenzo; E Vosburgh; R H Falk; V Sanchorawala; J Reisinger; S Dubrey; L M Dember; J L Berk; G Akpek; M LaValley; C O'hara; C F Arkin; D G Wright; M Skinner
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

7.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

8.  Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.

Authors:  R A Kyle; A Linos; C M Beard; R P Linke; M A Gertz; W M O'Fallon; L T Kurland
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

Review 9.  Current concepts on the pathogenesis of systemic amyloidosis.

Authors:  V Bellotti; G Merlini
Journal:  Nephrol Dial Transplant       Date:  1996       Impact factor: 5.992

10.  Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

Authors:  R L Comenzo; E Vosburgh; R W Simms; P Bergethon; D Sarnacki; K Finn; S Dubrey; D V Faller; D G Wright; R H Falk; M Skinner
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.